Drug Trial Radar · NCT05719701
Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Apr 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
80
Planned (sponsor's estimate)
Start
Mar 29, 2023
Primary completion
Jul 30, 2025
Study completion Dec 30, 2025
Sponsor
- Lead sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 9, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, non-randomized and open-label phase I/IIa clinical study to evaluate the safety, tolerability, and efficacy of ICP-490 in patients with relapsed and/or refractory multiple myeloma.
Conditions
- Relapsed and/or Refractory Multiple Myeloma
Interventions
ICP-490Drug
Several dose groups of ICP-490 are planned for the dose exploration.
DexamethasoneDrug
Oral Dexamethasone is administered on Days 1, 8, 15, and 22 of each 28-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase I : Incidence, type, and severity of adverse events (AEs) as judged according to NCI-CTCAE V5.0Time frame: Through study completion, an average of 3 years
- Phase I : Incidence, type, and severity of dose-limiting toxicities (DLTs)Time frame: Through study completion, an average of 3 years
- Phase I : RP2Ds and/or MTDsTime frame: Through study completion, an average of 3 years
- Phase II : ORR (defined as sCR + CR + VGPR + PR) assessed according to IMWG criteria.Time frame: Through study completion, an average of 3 years
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Peking University People's Hospital
Beijing, Beijing Municipality, China · Recruiting
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Not yet recruiting
Henan Cancer Hosptital
Zhengzhou, Henan, China · Not yet recruiting
Shengjing Hospital of China Medical University
Shenyang, Liaoning, China · Not yet recruiting
Renji Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China · Not yet recruiting
The First Affiliated Hospital,Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.